MA54223B1 - Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one en tant qu'inhibiteurs de hpk1 pour le traitement du cancer - Google Patents
Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one en tant qu'inhibiteurs de hpk1 pour le traitement du cancerInfo
- Publication number
- MA54223B1 MA54223B1 MA54223A MA54223A MA54223B1 MA 54223 B1 MA54223 B1 MA 54223B1 MA 54223 A MA54223 A MA 54223A MA 54223 A MA54223 A MA 54223A MA 54223 B1 MA54223 B1 MA 54223B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyridin
- pyrrolo
- dihydro
- derivatives
- cancer treatment
- Prior art date
Links
- QDSJMVZVUSYEMY-UHFFFAOYSA-N 2,3-dihydropyrrolo[3,4-c]pyridin-1-one Chemical class N1=CC=C2C(=O)NCC2=C1 QDSJMVZVUSYEMY-UHFFFAOYSA-N 0.000 title abstract 2
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 101100177670 Caenorhabditis elegans hpk-1 gene Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 108010002838 hematopoietic progenitor kinase 1 Proteins 0.000 abstract 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne des dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one de formule générale (i) et des sels pharmaceutiquement acceptables de ceux-ci, utilisés en tant qu'inhibiteurs de kinase progénitrice hématopoïétique 1 (hpk1), r1, r1a, r2, r3, r4 et (r5)a étant tels que définis dans la description, des compositions pharmaceutiques comprenant de tels composés et et des compositions pour le traitement d'une croissance cellulaire anormale, y compris le cancer. Un exemple particulier du composé est, par exemple, 4-[(méthylamino)méthyl]-6- [méthyl(propan-2-yl)amino]-2-[6-(4-propyl-4h-l,2,4-triazol-3-yl) pyridin-2-yl]-2,3-dihydro-lh-pyrrolo[3,4-c]pyridin-l-one. La présente invention concerne la préparation de composés donnés à titre d'exemple ainsi que des données pharmacologiques de ceux-ci (par exemple des pages 82 à 211; exemples 1 à 188; tableaux 1 à 5).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767602P | 2018-11-15 | 2018-11-15 | |
| PCT/IB2019/059702 WO2020100027A1 (fr) | 2018-11-15 | 2019-11-12 | Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one servant d'inhibiteurs de hpk1 pour le traitement du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54223A MA54223A (fr) | 2022-02-23 |
| MA54223B1 true MA54223B1 (fr) | 2023-10-31 |
Family
ID=77369712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54223A MA54223B1 (fr) | 2018-11-15 | 2019-11-12 | Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one en tant qu'inhibiteurs de hpk1 pour le traitement du cancer |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR117073A1 (fr) |
| MA (1) | MA54223B1 (fr) |
-
2019
- 2019-11-12 MA MA54223A patent/MA54223B1/fr unknown
- 2019-11-14 AR ARP190103343A patent/AR117073A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA54223A (fr) | 2022-02-23 |
| AR117073A1 (es) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551117A1 (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| US6803371B2 (en) | Purine inhibitors of protein kinases, G proteins and polymerases | |
| Domagala | Structure-activity and structure-side-effect relationships for the quinolone antibacterials | |
| WO2022235822A1 (fr) | Monothérapie d'inhibiteur de shp2 et ses utilisations | |
| MA63501A1 (fr) | Dérivés d'urée pouvant être utilisés pour traiter le cancer | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA58498B1 (fr) | Agonistes hétérocycliques de glp-1 | |
| CA2455181A1 (fr) | Derives de la benzimidazo[4,5-f]isoquinolinone | |
| MA30412B1 (fr) | Composés Pharmaceutiques | |
| US20210275522A1 (en) | Pharmaceutical compositions and use thereof | |
| MA34903B1 (fr) | Derives de type azaindazole ou diazaindazole utilises comme medicaments | |
| AR062207A1 (es) | Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer. | |
| TNSN08270A1 (fr) | Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale | |
| MA26991A1 (fr) | Triazolopyridines servant d'agents anti-inflammatoires | |
| BRPI0713253A2 (pt) | método de inibição de pde4, método de tratamento de um doença mediada por pde4, composto e composição farmacêutica | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| HUP0402352A2 (hu) | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| CA2687265A1 (fr) | Inhibiteurs de la p70 s6 kinase | |
| AR027464A1 (es) | Oxamidas que son inhibidores de la inosina monofosfato deshidrogenasa (impdh) | |
| RU2007110629A (ru) | Ингибиторы днк-пк | |
| MA31170B1 (fr) | Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer | |
| MA50069B1 (fr) | Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique | |
| Kumar et al. | Synthesis and in vitro anti-tubercular evaluation of 1, 2, 3-triazole tethered β-lactam–ferrocene and β-lactam–ferrocenylchalcone chimeric scaffolds | |
| MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
| MA54223B1 (fr) | Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one en tant qu'inhibiteurs de hpk1 pour le traitement du cancer |